Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (not reported) · patients with trigeminal neuralgia
1 finding from 1 review
Relief of pain · patients with trigeminal neuralgia
Proparacaine hydrochloride 0.5% eye drops showed no clear difference in immediate improvement in pain relief Number of participants improved… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
1 finding from 1 review
Withdrawals due to adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
Topiramate 200 to 400 mg probably leads to higher adverse event withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
RR 3.4 [4.3, 7.1]
1038 participants
Moderate
Serious adverse events · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
Topiramate 200 to 400 mg showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.6, 1.3]
1586 participants
Moderate
Death · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term overall improvement (three months or less) · patients with CTS
Therapeutic ultrasound may leads to higher short‐term overall improvement (three months or less) compared with placebo (low certainty).
1 finding from 1 review
Adverse effects · patients with CTS
1 finding from 1 review
Short‐term improvement in pain and/or paraesthesia (after seven weeks of treatment) Scale from: zero to 10 · patients with CTS
1 finding from 1 review
Change in grip strength · patients with CTS
1 finding from 1 review
Long‐term improvement in CTS symptoms (number of participants with complete remission of subjective symptoms) (six months · patients with CTS
Therapeutic ultrasound may leads to higher long‐term improvement in CTS symptoms (number of participants with… compared with placebo (low certainty).
1 finding from 1 review
Long‐term improvement in pain and/or paraesthesia (six months · patients with CTS
1 finding from 1 review